0001929354-23-000008.txt : 20230516 0001929354-23-000008.hdr.sgml : 20230516 20230516172343 ACCESSION NUMBER: 0001929354-23-000008 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230512 FILED AS OF DATE: 20230516 DATE AS OF CHANGE: 20230516 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Caissa Capital Management ltd. CENTRAL INDEX KEY: 0001929354 STATE OF INCORPORATION: D8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37590 FILM NUMBER: 23928788 BUSINESS ADDRESS: STREET 1: PALM GROVE HOUSE STREET 2: WICKHAMS CAY 1 ROAD TOWN CITY: TORTOLA STATE: D8 ZIP: VG1110 BUSINESS PHONE: 00377 99 90 25 95 MAIL ADDRESS: STREET 1: PALM GROVE HOUSE STREET 2: WICKHAMS CAY 1 ROAD TOWN CITY: TORTOLA STATE: D8 ZIP: VG1110 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Avalo Therapeutics, Inc. CENTRAL INDEX KEY: 0001534120 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 450705648 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 540 GAITHER ROAD STREET 2: SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 410-522-8707 MAIL ADDRESS: STREET 1: 540 GAITHER ROAD STREET 2: SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: Cerecor Inc. DATE OF NAME CHANGE: 20111102 4 1 primary_doc.xml PRIMARY DOCUMENT X0407 4 2023-05-12 0 0001534120 Avalo Therapeutics, Inc. AVTX 0001929354 Caissa Capital Management ltd. PALM GROVE HOUSE WICKHAMS CAY 1 ROAD TOWN TORTOLA D8 VG1110 VIRGIN ISLANDS, BRITISH 0 0 1 0 0 Common stock 2023-05-12 4 P 0 2285 2.45 A 1344985 I See Footnote (1) Common stock 2023-05-15 4 P 0 1715 2.5459 A 1346700 I See Footnote (1) Common stock 2023-05-16 4 P 0 379 2.75 A 1347079 I See Footnote (1) Common stock 182300 D Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.45 to $2.79, inclusive. These shares are directly owned by Mr. Golestaneh in his personal capacity. Cambyz Golestaneh, Title: Director 2023-05-16